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ABSTRACT 
Glomerular filtration rate (GFR) is the best index for kidney function; however, the applicability 
of GFR estimating equations in sub-Saharan African populations remains unclear. In a cross-
sectional study of adults living in Kinshasa, Democratic Republic of Congo (n = 210) and 
Abidjan, Ivory Coast (n = 284), we evaluated the performance of creatinine and cystatin C-based 
equations using plasma clearance of iohexol as the reference standard. The race coefficient did 
not improve the performance of creatinine-based GFR estimates; in fact, both the Modification of 
Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology (CKD-EPI) equations 
performed better without the race coefficient in participants with GFR ≥60 mL/min/1.73m2. 
The CKD-EPI and Full Age Spectrum (FAS) equations were unbiased and had similar precision 
(SD of 17.9 versus 19 mL/min/1.73 m2) and accuracy within 30% (P30, 86.7% versus 87.4%) in 
participants with GFR ≥60 mL/min/1.73m2. Both equations performed poorly in the subgroup 
with measured GFR < 60 mL/min/1.73m2 (n=80), but the FAS equation had smaller bias (— 
4.8 mL/min/1.73m2 versus —7.7 mL/min/1.73m2 for CKD-EPI) and higher P30 (56.3% versus 
31.3% for CKD-EPI). The corresponding equations including cystatin C alone or in combination 
with creatinine had similar performance. In a sub-Saharan African population, adjustment for 
race did not improve the performance of GFR estimating equations. The creatinine-based FAS 
and CKD-EPI equations performed reasonably well and were comparable when GFR was ≥ 60 
mL/min/1.73m2. Cystatin C did not improve performance. The FAS equation may be preferable 
when GFR is < 60 mL/min/1.73m2, but this should be confirmed in larger studies.
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Chronic kidney disease (CKD) is recognized as a worldwide public health problem.1-4 CKD is 
defined as the presence of persistent kidney damage (most of the time albuminuria) and/or 
decreased glomerular filtration rate (GFR) (<60 ml/min per 1.73 m2) for >3 months. Based on 
these 2 criteria (GFR and albuminuria), a staging system is proposed.5 Adverse outcomes of CKD 
such as end-stage renal disease, cardiovascular disease, and premature death can be prevented 
or delayed when treatment is initiated in the early stages of disease.6-8 Prevention is of 
paramount importance in low-income countries with no or limited access to dialysis 
techniques.2,9,10 In this context, GFR is the best quantitative marker of renal function. 
Measurement of GFR by using reference methods is, however, not easily feasible, especially in 
low-income countries. In clinical practice, GFR is thus estimated from endogenous biomarkers 
including creatinine and cystatin C (CysC),11, 2 those biomarkers being used in equations with 
other variables such as age, sex, and potentially ethnicity. Nowadays, the Modification of Diet in 
Renal Disease (MDRD)13 and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)14 
creatinine-based equations are the most used. Recently, a new equation, the "Full Age Spectrum" 
(FAS),15 was developed using serum creatinine (SCr) normalized or rescaled by the median 
normal creatinine concentration (Q) for age and sex.15,16 A mathematical factor is also applied to 
reflect the physiological decrease in GFR with aging.17 This concept allows the use of the same 
equation for different biomarkers and for subjects ranging from 2-years-old to the aging people 
(see Supplementary Methods for more details on the FAS equation and Q values). However, this 
equation has only been validated in Whites. Also, relatively few studies have considered the 
performance of the CKD-EPI and MDRD equations in African people, and most were focused on 
healthy adult black Africans and/or in one country.18-20 In the present analysis, we evaluated the 
performance of different equations (Table 1) for GFR estimation in a large cohort of sub-Saharan 
African people from 2 countries, including patients with CKD. Our goal was to study 3 topics of 
clinical interest for nephrologists in Africa regarding estimating GFR. First, we studied the 
relevance of ethnic corrections in the existing equations. The MDRD and CKD-EPI equations 
were thus considered and compared with and without the African American ethnic factors (ef) 
(MDRD ef or MDRD and CKD-EPI ef or CKD-EPI).18,19,21,22 In the same view, specific Q values for 
African people were proposed for the creatinine-based FAS equation. The creatinine-based FAS 
equation was considered with these Q values (FAS af) or with the values for Whites (FAS). 
Second, we compared the performance of different creatinine-based equations, as creatinine is 
nowadays the only biomarker used in developing countries. Third, we studied the potential 
added value of CysC-based equations (FAS CysC and CKD-EPI CysC; CysC-based equations do not 
require ethnic adaptation) and equations combining both biomarkers (CKD-EPI combined and 
FAS combined) in each equation model (CKD-EPI and MDRD vs. CKD-EPI CysC or CKD-EPI 






Table 1. Creatinine- and cystatin C-based equations for glomerular filtration rate estimation 
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MDRD 175 x SCr-1.154 x age-0.203 x (0.742 if female) x (1.212 if black) 
CKD-EPI SCr  
  Female  
   SCr ≤0.7 mg/dl 144 x (SCr/0.7)-0.329 x 0.993age x (1.159 if black) 
   SCr >0.7 mg/dl 144 x (SCr/0.7)-1.209 x 0.993age x (1.159 if black) 
  Male  
   SCr ≤0.9 mg/dl 141 x (SCr/0.9)-0∙411 x 0.993age x (1.159 if black) 
   SCr >0.9 mg/dl 141 x (SCr/0.9)-1.209 x 0.993age x (1.159 if black) 
   CKD-EPI CysC  
   CysC ≤0.8 mg/l 133 x (CysC/0.8)-0∙499 x 0.996age x (0.932 if female) 
   CysC >0.8 mg/l 133 x (CysC/0.8)-1.328 x 0.996age x (0.932 if female) 
   CKD-EPI combined  
   Female  
   SCr ≤0.7 mg/dl and CysC ≤0.8 mg/dl 130 x (SCr/0.7)-0∙248 x (CysC/0.8)-0∙375 x 0.995age x (1.08 if 
black) 
   SCr ≤0.7 mg/dl and CysC >0.8 mg/dl 130 x (SCr/0.7)-0∙248 x (CysC/0.8)-0∙711 x 0.995age x (1.08 if 
black) 
   SCr >0.7 mg/dl and CysC ≤0.8 mg/dl 130 x (SCr/0.7)-0∙601 x (CysC/0.8)-0∙375 x 0.995age x (1.08 if 
black) 
   SCr >0.7 mg/dl and CysC >0.8 mg/dl 130 x (SCr/0.7)-0∙601 x (CysC/0.8)-0∙711 x 0.995age x (1.08 if 
black) 
   Male  
   SCr ≤0.9 mg/dl and CysC ≤0.8 mg/dl 135 x (SCr/0.9)-0∙207 x (CysC/0.8)-0∙375 x 0.995age x (1.08 if 
black) 
   SCr ≤0.9 mg/dl and CysC >0.8 mg/dl 135 x (SCr/0.9)-0∙207 x (CysC/0.8)-0∙711 x 0.995age x (1.08 if 
black) 
   SCr >0.9 mg/dl and CysC ≤0.8 mg/dl 135 x (SCr/0.9)-0∙601 x (CysC/0.8)-0∙375 x 0.995age x (1.08 if 
black) 
   SCr >0.9 mg/dl and CysC >0.8 mg/dl 135 x (SCr/0.7)-0∙601 x (CysC/0.8)-0∙711 x 0.995age x (1.08 if 
black) 
FAS  
   SCr 107.3/(SCr/Qcrea) when 2 ≤ age ≤ 40 yr 
 107.3/(SCr/Qcrea) [x (0.988) (age-40) when age >40 yr] 
   CysC 107.3/(CysC/Qcys) [x (0.988)(age-40) when age >40 yr] 
   Combined 107.3/[α x (SCr/Qcrea) + (1-α)x (CysC/Qcys)] [x 0.988(age-40) 
when age >40 yr] (α = 0.5) 
CKD-EPI combined, Chronic Kidney Disease Epidemiology Collaboration equation combining creatinine and cystatin C; CKD-EPI 
CysC, Chronic Kidney Disease Epidemiology Collaboration equation based on cystatin C; CKD-EPI SCr, Chronic Kidney Disease 
Epidemiology Collaboration equation based on serum creatinine without the ethnic correction factor; CysC, cystatin C; FAS, Full Age 
Spectrum; MDRD, Modification of Diet in Renal Disease; Qcrea, Q value for serum creatinine; Qcys, Q value for cystatin C; SCr, serum 
creatinine. 
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GENERAL CHARACTERISTICS OF THE STUDY POPULATION 
Table 2 presents the general characteristics of participants in the whole cohort and according to 
sex. A total of 494 (46.4% of women) adult participants were included in the present study. The 
median age was 38 years (interquartile range, 30-53 years); the median body surface area and 
body mass index were 1.76 m2 (interquartile range, 1.63-1.88 m2) and 24 kg/m2 (interquartile 
range, 21-28 kg/m2), respectively. The median measured GFR (mGFR) of participants was 88 
ml/min per 1.73 m2 (interquartile range, 74-100 ml/min per 1.73 m2). 
Table 2. General characteristics of the study population 
Variable Overall (N = 
494) 
Male (n = 265) Female (n = 
229) 
P (male vs. 
female) 
Age (yr) 38 (30-53) 38 (30-52) 39 (30-53) 0.9934 
Weight (kg) 66 (59-77) 66 (60-75) 67 (58-79) 0.9383 
Height (cm) 166 (161-173) 172 (167-177) 162 (157-165) <0.0001 
BSA (m2) 1.76 (1.63-1.88) 1.78 (1.69-1.89) 1.72 (1.59-1.86) <0.0001 
BMI (kg/m2) 23.7 (20.8-27.6) 22.5 (20.3-25.1) 25.3 (22.3-29.7) <0.0001 
SCr (mg/dl) 0.93 (0.79-1.15) 1.04 (0.92-1.28) 0.80 (0.71-0.93) <0.0001 
CysC (mg/l) 0.89 (0.79-1.06) 0.92 (0.81-1.14) 0.87 (0.78 -1.00) 0.0017 
mGFR (ml/min per 1.73 m2) 88 (74-100) 87 (72-101) 87 (76-100) 0.9426 
MDRD (ml/min per 1.73 m2) 81 (65-93) 81 (63-94) 79 (67-91) 0.9997 
MDRD ef (ml/min per 1.73 m2) 98 (79-112) 99 (76-115) 96 (81-110) 0.9997 
CKD-EPI SCr (ml/min per 1.73 m2) 92 (72-105) 91 (68-104) 92 (75-105) 0.2771 
CKD-EPI SCr ef (ml/min per 1.73 m2) 106 (83-122) 106 (79-121) 106 (87-122) 0.2771 
CKD-EPI CysC (ml/min per 1.73 m2) 95 (72-111) 96 (69-113) 94 (73-109) 0.8340 
CKD-EPI combined (ml/min per 1.73 m2) 93 (73-106) 94 (69-106) 92 (74-105) 0.8867 
CKD-EPI combined ef (ml/min per 1.73 
m2) 
101 (79-114) 101 (75-115) 100 (80-114) 0.8867 
FAS SCr (ml/min per 1.73 m2) 88 (70-101) 89 (67-102) 88 (72-100) 0.8847 
FAS SCr af (ml/min per 1.73 m2) 93 (73-106) 95 (71-108) 90 (74-102) 0.1689 
FAS CysC (ml/min per 1.73 m2) 93 (71-109) 93 (67-105) 96 (74-111) 0.0173 
FAS combined (ml/min per 1.73 m2) 92 (73-103) 91 (70-102) 92 (74-104) 0.1452 
FAS combined af (ml/min per 1.73 m2) 94 (74-106) 94 (72-106) 94 (75-105) 0.5116 
BMI, body mass index; BSA, body surface area; CKD-EPI combined, Chronic Kidney Disease Epidemiology Collaboration equation 
combining creatinine and cystatin C; CKD-EPI combined ef, Chronic Kidney Disease Epidemiology Collaboration equation with the 
ethnic factor; CKD-EPI CysC, CKD-EPI equation based on cystatin C; CKD-EPI SCr, Chronic Kidney Disease Epidemiology 
Collaboration equation based on serum creatinine without the ethnic correction factor; CKD-EPI SCr ef, Chronic Kidney Disease 
Epidemiology Collaboration equation based on serum creatinine with the ethnic factor; CysC, cystatin C; FAS combined, Full Age 
Spectrum equation based on creatinine and cystatin C with White Q; FAS combined af, Full Age Spectrum equation combined with 
African Q; FAS CysC, FAS equation based on cystatin C; FAS SCr, Full Age Spectrum equation based on serum creatinine with White Q; 
FAS SCr af, Full Age Spectrum equation based on serum creatinine with African Q; MDRD, Modification of Diet in Renal Disease; 
MDRD ef, Modification of Diet in Renal Disease with the ethnic factor; mGFR, measured glomerular filtration rate; SCr, serum 
creatinine. Data are median (interquartile range). 
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COMPARISON OF EQUATIONS WITH OR WITHOUT ETHNIC CORRECTIONS 
In the whole cohort (N = 494), both FAS SCr and CKD-EPI were unbiased whereas FAS SCr af, 
MDRD, MDRD ef, and CKD-EPI ef had a significant bias. Among these biased equations, bias of 
MDRD ef and MDRD had opposite signs (8.2 ml/min per 1.73 m2 vs. —7.8 ml/min per 1.73 m2) 
but equal absolute magnitude (8.2 ml/min per 1.73 m2 vs. 7.8 ml/min per 1.73 m2). Regarding 
precision, FAS SCr and FAS SCr af had the same precision (SD, 18.7 and 19.6 ml/min per 1.73 m2, 
respectively) but MDRD ef and CKD-EPI ef had lower precision than did MDRD and CKD-EPI, 
respectively (SD, 19.4 ml/min per 1.73 m2 vs. 23.3 ml/min per 1.73 m2 and 18.1 ml/min per 1.73 
m2 vs. 21.3 ml/min per 1.73 m2, respectively). The accuracy within 30% (P30) of CKD-EPI ef was 
lower than that of CKD-EPI (64.6% vs. 77.7%; P < 0.0001), whereas P30 of MDRD (76.1%) was 
not different from that of MDRD ef (73.3%). Also, both FAS SCr and FAS SCr af had similar 
accuracy (82.4% vs. 80.6%, respectively) (Table 3). 
In the subgroup with GFR >60 ml/min per 1.73 m2 (n = 414), the same observations were made 
as in the whole cohort, except that absolute bias of MDRD ef was significantly higher than that of 
MDRD (10.4 ml/min per 1.73 m2 vs. 7.6 ml/min per 1.73 m2; P = 0.0033) and that precision of 
CKD-EPI (SD, 17.9 ml/min per 1.73 m2) was similar to that of CKD-EPI ef (SD, 19.9 ml/min per 
1.73 m2) (Supplementary Table S1). 
In the subgroup with GFR <60 ml/min per 1.73 m2 (n = 80), MDRD ef, CKD-EPI ef, and FAS SCr 
af appeared unbiased whereas FAS SCr, MDRD, and CKD-EPI had bias significantly different from 
zero (—4.8 ml/min per 1.73 m2 vs. —9.0 ml/min per 1.73 m2 vs. —7.7 ml/min per 1.73 m2, 
respectively). Precision of all equations was comparable. P30 of equations without ethnic 
corrections was not different from P30 of the corresponding equation with ethnic corrections 
(Supplementary Table S2). 
Table 3. Performance of equations in the whole cohort (N = 494) 
Equation Absolute bias 
(95% CI) 
Absolute SD Accuracy within 30% 
(95% CI) 
Lin's CCC (95% 
CI) 
MDRD -7.8 (-9.5 to -6.1) 19.4 76.1 (72.3 to 79.9) 0.73 (0.67 to 
0.78) 
MDRD ef 8.2 (6.1 to 10.2) 23.3 73.3 (69.4 to 77.2) 0.70 (0.61 to 
0.77) 
CKD-EPI 0.0 (-1.6 to 1.6) 18.1 77.7 (74.1 to 81.4) 0.81 (0.76 to 
0.84) 
CKD-EPI ef 13.3 (11.4 to 15.2) 21.3 64.6 (60.3 to 68.8) 0.71 (0.66 to 
0.76) 
FAS SCr -1.5 (-3.1 to 0.2) 18.7 82.4 (79.0 to 85.8) 0.78 (0.72 to 
0.82) 
FAS SCr af 2.5 (0.7 to 4.2) 19.6 80.6 (77.1 to 84.1) 0.77 (0.70 to 
0.82) 
CKD-EPI CysC 3.2 (1.5 to 4.8) 18.5 78.7 (75.1 to 82.4) 0.80 (0.75 to 
0.83) 
FAS CysC 3.7 (2.0 to 5.3) 18.7 84.2 (81.0 to 87.4) 0.78 (0.72 to 
0.82) 
CKD-EPI combined 1.1 (-0.4 to 2.5) 16.6 79.2 (75.6 to 82.7) 0.83 (0.79 to 
0.86) 
Published in : Kidney International (2019) 95, pp. 1181-1189 
DOI: https://doi.org/10.1016/ j.kint.2018.11.045  




CKD-EPI combined ef 7.8 (6.2 to 9.4) 18.1 76.7 (73.0 to 80.5) 0.80 (0.75 to 
0.83) 
FAS combined 0.1 (-1.3 to 1.5) 15.8 86.4 (83.4 to 89.5) 0.84 (0.79 to 
0.87) 
FAS combined af 2.1 (0.7 to 3.5) 16.1 85.4 (82.3 to 88.6) 0.83 (0.78 to 
0.86) 
CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CKD-EPI combined, Chronic Kidney Disease 
Epidemiology Collaboration equation combining creatinine and cystatin C; CKD-EPI combined ef, Chronic Kidney Disease 
Epidemiology Collaboration equation with the ethnic factor; CKD-EPI CysC, Chronic Kidney Disease Epidemiology Collaboration 
equation based on cystatin C; FAS combined, Full Age Spectrum equation based on creatinine and cystatin C with White Q; FAS 
combined af, Full Age Spectrum equation combined with African Q; FAS CysC, Full Age Spectrum equation based on cystatin C; FAS 
SCr, Full Age Spectrum equation based on serum creatinine with White Q; FAS SCr af, Full Age Spectrum equation based on serum 
creatinine with African Q; Lin's CCC , Lin's concordance correlation coefficient; MDRD, Modification of Diet in Renal Disease; MDRD 
ef, Modification of Diet in Renal Disease with the ethnic factor. 
COMPARISON OF EQUATIONS BASED ON SCR 
Because of the poorer results of equations with ethnic corrections, only equations without ethnic 
corrections have been compared in this section. In the whole cohort (N = 494), FAS SCr and 
CKD-EPI were unbiased whereas MDRD significantly underestimated GFR. The 3 equations had 
the same precision. P30 of FAS SCr was significantly higher than that of CKD-EPI (82.4% vs. 
77.7%; P =0.0022) and MDRD (82.4% vs. 76.1%; P = 0.0002), with no difference between 
MDRD and CKD-EPI (Table 3). 
In the subgroup with GFR >60 ml/min per 1.73 m2 (n = 414), the same observations were made 
as in the whole cohort, except that P30 was not different between the 3 equations 
(Supplementary Table S1). 
In the subgroup with GFR <60 ml/min per 1.73 m2 (n = 80), all equations underestimated GFR 
but absolute bias of FAS SCr was smaller than that of CKD-EPI (4.8 ml/min per 1.73 m2 vs. 7.7 
ml/min per 1.73 m2 ; P < 0.0001) and MDRD (4.8 ml/min per 1.73 m2 vs. 9.0 ml/min per 1.73 m2 
; P < 0.0001). Absolute bias of MDRD was larger than that of CKD-EPI (P < 0.0001). Precision of 
all equations was comparable. P30 of FAS SCr (56.3%) was significantly higher than that of 
MDRD (31.3%; P < 0.0001) and CKD-EPI (31.3%; P < 0.0001) (Supplementary Table S2). 
Comparisons of creatinine-based equations are shown in Table 4. 
POTENTIAL ADDED VALUE OF CYSC 
The CysC-based or combined equations were compared with the corresponding SCr-based 
equations without ethnic corrections, that is, CKD-EPI with CKD-EPI CysC or CKD-EPI combined 
and FAS SCr with FAS CysC or FAS combined. In the whole cohort (N = 494), FAS SCr, FAS 
combined, CKD-EPI, and CKD-EPI combined were unbiased whereas CKD-EPI CysC and FAS CysC 
overestimated GFR. Bias of FAS CysC was not different from that of CKD-EPI CysC (3.7 ml/ min 
per 1.73 m2 vs. 3.2 ml/min per 1.73 m2). CKD-EPI (SD, 18.1 ml/min per 1.73 m2), CKD-EPI CysC 
(SD, 18.5 ml/min per 1.73 m2), and CKD-EPI combined (SD, 16.6 ml/min per 1.73 m2) had the 
same precision. Also, FAS SCr (SD, 18.7 ml/ min per 1.73 m2) and FAS CysC (SD, 18.7 ml/min per 
1.73 m2) had the same precision, but FAS combined (SD, 15.8 ml/min per 1.73 m2) had higher 
precision than did FAS SCr (P < 0.0001) and FAS CysC (P < 0.0001). P30 of CKD-EPI (77.7%) 
was not different from that of CKD-EPI CysC (78.7%) or CKD-EPI combined (79.2%), and P30 of 
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FAS SCr (82.4%) was not different from that of FAS CysC (84.2%) or FAS combined (86.4%) 
(Table 3). 
In the subgroup with GFR >60 ml/min per 1.73 m2 (n = 414) (Supplementary Table S1), the 
same observations were made regarding bias, except that CKD-EPI combined also overestimated 
GFR. Absolute bias of CKD-EPI combined was lower than that of CKD-EPI CysC (2.8 ml/min per 
1.73 m2 vs. 4.9 ml/min per 1.73 m2 ; P < 0.0001) and FAS CysC (2.8 ml/min per 1.73 m2 vs. 4.4 
ml/min per 1.73 m2 ; P = 0.0026). Regarding precision and P30, the same observations were 
made as in the whole cohort (Supplementary Table S1). 
In the subgroup with GFR <60 ml/min per 1.73 m2 (n = 80), only FAS CysC and FAS combined 
were unbiased whereas all other equations underestimated GFR. Bias of CKD-EPI was not 
different from that of CKD-EPI CysC or CKD-EPI combined. Precision of all equations was 
comparable. P30 of CKD-EPI (31.3%) was similar to that of CKD-EPI CysC (41.3%) or CKD-EPI 
combined (28.8%). P30 of FAS SCr (56.3%) was not different from that of FAS CysC (75%) or 
FAS combined (61.3%) (Supplementary Table S2). 
 
Table 4. Comparison of performance of the 3 creatinine-based equations (without ethnic 
corrections) 
Variable MDRD CKD-EPI FAS SCr 
Bias    
   Whole cohort (N = 494) -7.8 (-9.5 to -6.1 )d 0.0 (-1.6 to 1.6)a -1.5 (-3.1 to 0.2)a 
   Participants with GFR ≥60 ml/min per 1.73 m2 (n 
= 414) 
-7.6 (-9.5 to -5.7)d 1.5 (-0.2 to 3.3)a -0.9 (-2.7 to 1.0)a 
   Participants with GFR <60 ml/min per 1.73 m2 (n 
= 80) 
-9.0 (-12.6 to -
5.4)d 
-7.7 (-11.6 to -
3.8)c 
-4.8 (-8.5 to -1.1 )b 
Precision (SD)    
   Whole cohort (N = 494) 19.4b 18.1a 18.7b 
   Participants with GFR ≥60 ml/min per 1.73 m2 (n 
= 80) 
20.0b 17.9a 19.0b 
   Participants with GFR <60 ml/min per 1.73 m2 (n 
= 414) 
16.2a 17.4b 16.6b 
P30    
   Whole cohort (N = 494) 76.1 (72.3 to 
79.9)c 
77.7 (74.1 to 
81.4)c 
82.4 (79.0 to 
85.8)a 
   Participants with GFR ≥60 ml/min per 1.73 m2 (n 
= 414) 
84.8 (81.3 to 
88.3)b 
86.7 (83.4 to 90)b 87.4 (84.2 to 
90.7)a 
   Participants with GFR <60 ml/min per 1.73 m2 (n 
= 80) 
31.3 (20.9 to 
41.6)c 
31.3 (20.9 to 
41.6)c 
56.3 (45.1 to 
67.4)a 
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; FAS SCr, Full Age Spectrum equation based on serum creatinine with 
White Q; MDRD, Modification of Diet in Renal Disease; P30, accuracy within 30%. 
Data are median (interquartile range). All bias and precision results are expressed in ml/min per 1.73 m2. All P30 results are 
expressed in percentage. Bias: aUnbiased results. Among biased results b-d, absolute bias c is larger than b and absolute bias d is larger 
than c. Precision: SDs are not statistically significantly different between equations, abest results; bworst results. P30: aThe best result 
among the 3 equations. bResults not different from the best result. cResults with the lowest P30 of the 3 equations, significantly 
different from a. Level of significance was <0.0045. 
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Figure 1. Bland and Altman plots for estimating glomerular filtration rate (eGFR) and measured 
glomerular filtration rate (mGFR) in the whole population. The x axis represents the mean of 
eGFR and mGFR. The y axis represents the difference between eGFR and mGFR. The first line has 
graphs of creatinine-based equations; the second line, graphs of cystatin C-based equations; and 
the third line, graphs of combined equations. In each plot, the central dotted line represents bias, 
and the range between 2 other lines represents 95% limits of agreement (=1.96 x SD). Arrows 
represent outliers. CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CKD-EPI 
combined, Chronic Kidney Disease Epidemiology Collaboration equation combining creatinine 
and cystatin C; CKD-EPI combined ef, Chronic Kidney Disease Epidemiology Collaboration 
equation with the ethnic factor; CKD-EPI CysC, Chronic Kidney Disease Epidemiology 
Collaboration equation based on cystatin C; FAS combined, Full Age Spectrum equation based on 
creatinine and cystatin C with White Q; FAS combined af, Full Age Spectrum equation combined 
with African Q; FAS CysC, Full Age Spectrum equation based on cystatin C; FAS SCr, Full Age 
Spectrum equation based on serum creatinine with White Q; FAS SCr af, Full Age Spectrum 
equation based on serum creatinine with African Q; MDRD, Modification of Diet in Renal Disease; 




Figure 2. Comparison of measured glomerular filtration rate (mGFR) values in healthy Whites, 
Congolese, and Ivorian subjects.  Solid gray circles represent mGFR results and solid black lines 
represent 2.5th percentile (Pct), 50th Pct, and 97.5th Pct for mGFR in the Ivorian population (n 
= 237).18 Solid black circles with error bars represent upper and lower reference limits 
obtained from the meta-analysis including 633 White potential living kidney donors.26 Added 
white circles represent Congolese healthy subjects (n = 95). 
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Table 5. Percentage of participants classified with eGFR in the same staging as with mGFR 
 Percentage of participants 
Equation correctly classified 
MDRD 52.4 
MDRD ef 58.1 
CKD-EPI 57.9 
CKD-EPI ef 57.1 
FAS SCr 59.3 
FAS SCr af 60.5 
CKD-EPI CysC 58.3 
FAS CysC 59.1 
CKD-EPI combined 60.3 
CKD-EPI combined ef 59.9 
FAS combined 59.7 
FAS combined af 61.3 
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CKD-EPI combined, Chronic Kidney Disease Epidemiology 
Collaboration equation combining creatinine and cystatin C; CKD-EPI combined ef, Chronic Kidney Disease Epidemiology 
Collaboration equation with the ethnic factor; CKD-EPI CysC, Chronic Kidney Disease Epidemiology Collaboration equation based on 
cystatin C; eGFR, estimated glomerular filtration rate; FAS combined, Full Age Spectrum equation based on Caucasian creatinine and 
cystatin C with Q; FAS combined af, Full Age Spectrum equation combined with African Q; FAS CysC, Full Age Spectrum equation 
based on cystatin C; FAS SCr, Full Age Spectrum equation based on serum creatinine with Caucasian Q; FAS SCr af, Full Age Spectrum 
equation based on serum creatinine with African Q; MDRD, Modification of Diet in Renal Disease; MDRD ef, Modification of Diet in 
Renal Disease with the ethnic factor; mGFR, measured glomerular filtration rate. 
BLAND AND ALTMAN PLOT, CONCORDANCE CORRELATION COEFFICIENT, AND 
CKD STAGING IN THE WHOLE COHORT 
Bland and Altman plots are shown in Figure 1. Regarding Lin's concordance correlation 
coefficients (CCCs), the single biomarker equations had CCCs of ~0.80, not statistically 
significantly different from each other, except for MDRD, MDRD ef, and CKD-EPI ef, where Lin's 
CCCs are closer to 0.70 and significantly different from those of others. The combined equations 
have significantly higher Lin's CCCs than do the single biomarker equations, except for CKD-EPI 
ef combined whose performance is less. 
The ability of equations to correctly classify a participant in the CKD staging was tested for each 
equation in the whole cohort. Equations had the same global performance, with 40% of 
participants being in a different CKD stage with equations than with mGFR (Table 5). The worst 
Published in : Kidney International (2019) 95, pp. 1181-1189 
DOI: https://doi.org/10.1016/ j.kint.2018.11.045  




equation was MDRD, with only 52.4% of participants being correctly classified, and the best 
equation was FAS combined af, with the same staging as mGFR in 61.3% of participants. 
PERCENTILES OF NORMAL MGFR 
African subjects considered as healthy were compared with percentiles previously established 
in healthy Whites. Figure 2 demonstrates that percentiles of normal GFR in healthy African 




In the present study, we compared the performance of different equations to estimate GFR in the 
largest cohort from sub-Saharan Africa ever described. SCr is still the best choice among renal 
biomarkers, especially in low-income countries, as this tool is cheap and easy to perform.27,28 
The first important question we wanted to ask was whether ethnic corrections (African 
American coefficient in MDRD and CKD-EPI and African-derived Q value in FAS) were accurate 
in the African context. We found that the ethnic factor (>1) in both MDRD and CKD-EPI 
equations are not accurate in our African population and overestimate GFR. This is particularly 
the case in healthy subjects with high GFR values. This inadequacy of the ethnic factor for these 
equations is probably explained by the fact that they have been developed in African American 
people with different anthropometrical characteristics. Indeed, sub-Saharan blacks have low 
muscle mass compared with African Americans, potentially secondary to poorer diet or overall 
health related to HIV infection or other chronic diseases. This point is illustrated by the 
relatively low body mass index and body surface area of our cohort (24 kg/m2 and 1.73 m2, 
respectively). It could be argued that MDRD ef, CKD-EPI ef, and FAS SCr af are unbiased in 
patients with CKD, contrary to the corresponding equations without ethnic factors, but precision 
and P30 are not different, and, more importantly, the global performance of these equations 
remained poor when GFR was <60 ml/min per 1.73 m2 (P30, between 41% and 51%). Even in 
African Americans, the ethnic factor has been questioned in subjects with high GFR values.21 
Previous data from Africa (and African European) also suggested that such an ethnic factor was 
not valuable.18-22,29,30 Regarding ethnicity, we showed that FAS SCr af had the same global 
performance as FAS SCr observed in Whites, both in patients with low GFR values and in 
subjects with high GFR values. This is easily explained, as Q af was not different from the Q 
values observed in Whites. This observation confirmed limited previous data suggesting that SCr 
normal values were comparable in Africa and Europe.17,31 Regarding reference values, we also 
confirmed that healthy people from West Africa or Central Africa have the same distribution of 
mGFR as Whites,17,18 notably with the same decrease in mGFR with aging.32 
Among the different SCr-based equations, both CKD-EPI and FAS-SCr equations had the same 
performance in the whole population and in subjects with GFR >60 ml/min per 1.73 m2. These 
equations are unbiased, have the same precision, and have the same P30 (only P30 in the whole 
population was slightly higher for FAS SCr than for CKD-EPI). The poor performance of MDRD 
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was expected in this population with high GFR values.14 In patients with GFR <60 ml/ min per 
1.73 m2, all equations were biased but bias was lower and P30 higher for FAS SCr than for MDRD 
or CKD-EPI. For the first time, FAS SCr was tested in a large African cohort, and our results 
confirmed the value of this equation, as suggested by several European studies.15,25,33,34 
CysC is a biomarker of interest, notably because its concentration is independent of any tubular 
secretion effect and of muscular mass.11,23,25 For this reason, most CysC-based equations 
developed until now are used without any correction for ethnicity.23,25,35 However, in our African 
cohort, we found no substantial added value for CysC when used alone or in combination with 
SCr in CKD-EPI equations. In FAS equations, we found that FAS combined was unbiased just like 
FAS SCr. Only precision of FAS combined was higher than that of FAS SCr and FAS CysC in the 
whole population and in subjects with high GFR values. In patients with CKD, FAS CysC and FAS 
combined were the only unbiased equations but precision and P30 were not different from 
those of FAS SCr (only a trend for FAS CysC compared to FAS SCr, 75% vs. 52.2%; P = 0.0107). 
The potential added values of FAS CysC and FAS combined deserve further evaluation in a larger 
sample of CKD. These results must also be discussed in the light of cost-effectiveness of a 
biomarker, namely, CysC, which is much more costly and less available in low-income countries. 
In our cohort, the performance of all SCr-based equations is particularly poor in patients with 
CKD (P30 of 31.6% for both MDRD and CKD-EPI, and of 56.3% for FAS SCr). Only FAS CysC had 
P30 around 75%. Even if this accuracy value is lower than accuracy values observed in European 
or North American studies,23,25,35 it is comparable to some results observed in Asia24,36 and 
Africa.20 These results are quite challenging. Several hypotheses can be proposed to explain such 
poor global performance. Some authors have actually suggested that SCr tubular secretion could 
be different in Africans and Whites,37 but this point is still debated.29 Another explanation could 
be the low GFR values of our population with CKD. Indeed, it is well known from the literature 
that performance of all equations, and notably P30, is poor in patients with low GFR values. 
Currently, no screening programs for the early detection of CKD are proposed in Ivory Coast and 
DRC Access to health care and laboratories is also more problematic. For these reasons, patients 
with CKD followed by nephrologists in these countries are more severely ill and are referred at 
later CKD stages than those in developing countries with better health care systems.10 This is 
reflected by several results: in our CKD subgroup (n = 96), we excluded 16 patients with very 
low GFR values (mGFR <15 ml/min per 1.73 m2). In the remaining 80 patients with CKD, the 
mean GFR value was still low at 34 ± 12 ml/min per 1.73 m2. Yet, precise estimates of kidney 
function are critically important for such patients because of their large implications for 
estimating the prevalence and classification of CKD for the appropriate management of 
comorbid conditions and medication dosing. Further studies in African patients with CKD are 
thus needed. 
Our study has several limitations. Even if it is the largest cohort of sub-Saharan African people 
with mGFR, the proportion of patients with CKD is still small. Moreover, our study was limited to 
African people living in Africa. Our conclusion might not be valid for Africans living in other 
continents. Ideally, our results should have included Whites as a sort of control group. Also, GFR 
was measured with iohexol plasma clearance, a recognized and accepted reference method,38-40 
whereas CKD-EPI and MDRD have been developed (in majority) with iothalamate urinary 
clearance data. Such urinary clearances are, however, much more cumbersome and costly than 
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plasma clearances, and this is particularly relevant in developing countries. Moreover, the CKD-
EPI equation has been favorably tested against iohexol plasma clearance in other cohorts.41 
Sensu stricto, the fact that iohexol plasma clearance has never been validated against urinary 
inulin clearance (the so-called criterion standard for mGFR) in African subjects can be 
considered as a limitation. Finally, the ability of equations to correctly classify the subject in the 
currently CKD classification system is limited, as ~ 60% of participants in the same CKD stage 
with estimating equations and with mGFR were observed. These results are similar to recent 
data published in Europe.42 
In conclusion, we showed that both MDRD and CKD-EPI equations perform better in our African 
population when the African American ethnic factors are omitted, especially in subjects with 
high GFR values. FAS SCr af has the same performance as FAS SCr. Among creatinine-based 
equations, FAS SCr and CKD-EPI equations performed similarly, and we suggest that FAS SCr 
could be slightly better in patients with CKD, but these results need to be confirmed in larger 
African CKD cohorts. Keeping in mind the economic aspect, it seems unreasonable to 
recommend CysC in Africa, but the interest of CysC (and more particularly of the FAS CysC 
equation) merits to be considered in patients with CKD and low GFR values. Further studies 
using this equation in this specific African population are also needed. 
METHODS 
This was a cross-sectional study enrolling 510 participants living in Kinshasa (n = 222), the 
capital of the DRC and in Abidjan (n = 288), the most populated city of Ivory Coast. Patients with 
low GFR values (<15 ml/min per 1.73 m2; n = 16) were excluded from the analyses because the 
performance of all equations was poor in this range of GFR. Analyses presented here thus 
concerned 494 participants (210 from DRC and 284 from Ivory Coast). In Kinshasa, participants 
were visited twice at home by trained research personnel, who recorded information on 
demographic characteristics, diet, smoking, alcohol consumption, and use of indigenous herbal 
remedies. Data about first-degree family relatives; medical history of kidney disease, 
hypertension, and diabetes; and current treatment were also recorded. All participants were 
asked to avoid medications that influence GFR (e.g., anti-inflammatory agents, diuretics, and 
renin-angiotensin blocking agents) and those that can interfere with creatinine secretion (e.g., 
cimetidine or trimethoprim). Briefly, medication was not allowed except for contraceptives in 
female participants. 
In DRC, healthy persons were randomly selected from the general population as described 
elsewhere.19 Healthy subjects were all those who did not have hypertension, diabetes mellitus, 
obesity, urinary abnormalities, and impaired renal function (GFR <60 or >130 ml/ min per 1.73 
m2). Patients with CKD were recruited from the general population and from the medical 
services (Renal Unit of Kinshasa University Hospital). They had a decrease in GFR (<60 ml/ min 
per 1.73 m2) with or without albuminuria. 
In Ivory Coast, healthy subjects were recruited from blood donors and healthy status was 
assessed by clinical and biological evaluation. Diabetes and hypertension were excluded, and 
subjects had normal biological results (HIV, hepatitis B or C, and GFR between 60 and 130 
Published in : Kidney International (2019) 95, pp. 1181-1189 
DOI: https://doi.org/10.1016/ j.kint.2018.11.045  




ml/min per 1.73 m2) and no albuminuria.18 Patients with CKD were recruited from patients 
followed by nephrologists at the university hospital of Abidjan. 
In the present analyses, the threshold proposed by the Kidney Disease: Improving Global 
Outcomes, that is, 60 ml/min per 1.73 m2, was used to define low and high GFR values.5 
In DRC, the study protocol was approved by the Ethics Committee of the Public Health School of 
the University of Kinshasa (N°ESP/CE/029/2015) and by the institutional review boards at each 
site. Written informed consent was obtained from all participants, and all participants with 
abnormal findings received counseling and educational pamphlets. 
In Ivory Coast, the study was approved by the national ethics committee (under the number 
039/MSLS/CNER-dkn). A written informed consent was obtained for all participants. 
GFR MEASUREMENT AND ESTIMATION 
GFR was measured using iohexol plasma clearance (Omnipaque, 240 mg I/ml, GE Healthcare, 
Machelen, Belgium) as the reference method.39,40 After verification of the participant's identity, a 
rest of 5 minutes was observed. The syringe with iohexol was weighed before and after the 
injection to an accuracy of 0.01 g. In the morning, a catheter was placed in a large vein of the 
forearm and 5 ml of blood was taken at time 0 for the determination of both SCr and CysC. By the 
same vein, 5 ml of iohexol was injected before removing the catheter and the empty syringe was 
weighed. Then, 4 blood samples were drawn from a different i.v. access (usually from the 
contralateral arm) at 120, 180, 240, and 300 minutes after the injection of iohexol. The blood 
sample was allowed to stand for 30 to 60 minutes before being centrifuged. After centrifugation, 
samples were stored at — 80 °C. Then, samples were shipped for iohexol measurement at the 
laboratory of the University of Liège, Belgium, and measured by liquid chromatography-tandem 
mass spectrometry43 or high performance liquid chromatography44 Concentrations of iohexol 
measured by high performance liquid chromatography and liquid chromatography-tandem 
mass spectrometry were calibrated by a factor previously described.45 To ensure the quality of 
iohexol measurements, the laboratory is accredited for the ISO 15189 standard and also 
participates in the interlaboratory quality test for iohexol conducted by Equalis AB (Uppsala, 
Sweden).39 mGFR was then calculated using the slope-intercept method and corrected using the 
Brochner-Mortensen equation.46 The results were normalized by body surface area by using the 
Gehan and Georges formula47 as follows: Body surface area — 0.0235 x weight0.51456 x 
height0.42246 
SCr levels were determined in the same laboratory by using an enzymatic method with an IDMS-
traceable calibrator using Roche Cobas (Roche Diagnostics, Mannheim, Germany).48 Serum CysC 
levels were measured by means of the latex immunoturbidimetric method using Roche Cobas 
(Roche Diagnostics) and standardized to ERM-DA 471/IFCC.49 
GFR (in ml/min per 1.73 m2) was estimated by using the following equations: MDRD, CKD-EPI, 
and FAS using SCr and/or CysC.13--15,25 The FAS equation was used with the Q values for Whites 
or Africans. African Q values were obtained by calculating the median creatinine concentration 
for age and sex of healthy subjects in the "PDMRA" (for "Prévalence, détection précoce et 
prévention des maladies rénales chroniques et facteurs de risque associés" that means 
prevalence, early detection, and prevention of CKD and associated risks) survey database 
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(unpublished data): 0.72 mg/dl for women and 0.96 mg/dl for men (see more details in 
Supplementary Methods). As a reminder, the corresponding Q values for Whites are 0.70 and 
0.90 mg/dl, respectively. The MDRD and CKD-EPI equations were studied with and without the 
ethnic correction factor (African American) (Table 1). 
STATISTICAL ANALYSES 
All analyses and calculations were performed using SAS 9.4 (SAS Institute Inc., Cary, NC). Data 
are expressed as mean ± SD when the distribution was normal and as median with interquartile 
range (quartile 1-quartile 3) when not. Normality was assessed using the Shapiro-Wilk test. The 
means and medians of 2 groups were compared using the Student f-test or the Mann-Whitney U 
test, respectively. We assessed the performance of equations using several statistical tools. Lin's 
CCC evaluated the degree to which pairs of observations fall on the 45° line through the origin. It 
is a measure of both correlation and agreement.50 Such CCC was calculated only in the large 
range of GFR (whole population), as all results in subgroups showed poor agreement because of 
the restriction of the range of GFR. Then, bias (the difference between eGFR and mGFR; 
systematic error) was calculated. Precision was evaluated by the SD of bias (random error). 
Biases were compared in 2 steps. First, we considered equations as unbiased when bias was not 
different from zero (when 95% confidence interval includes zero). Second, we compared 
absolute bias among biased equations by using the paired t test. Precision of equations were 
compared using the variance ratio test (F test). We also calculated P30. The difference in P30 
between eGFRs was determined using the exact McNemar test. 
Because we considered 12 equations, there were 66 [=(12 x 11)/ 2] pairwise comparisons of 
highly correlated equations, making the strict Bonferroni correction inappropriate, as it is too 
conservative. Given that our study is observational in nature and that we compare 1 equation 
with the 11 others, we propose to use P < 0.05/11 — 0.0045 to claim statistical significance. 
Finally, we also tested the ability of each equation to classify participants with eGFR in the same 
CKD staging as with mGFR. The Kidney Disease: Improving 
Global Outcomes classification was considered for this analysis: stage 1, ≥90 ml/min per 1.73 
m2; stage 2, between 60 and 89 ml/min per 1.73 m2; stage 3a, between 45 and 59 ml/min per 
1.73 m2; stage 3b, between 30 and 44 ml/min per 1.73 m2; stage 4, between 15 and 29 ml/min 
per 1.73 m2; and stage 5, <15 ml/min per 1.73 m2. In a final analysis, we compared the 
distribution (percentiles) of normal GFR in African subjects with a healthy status with the 
distribution observed in Whites as previously described.18,26 
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